19-Nor-1α, 25-dihydroxyvitamin D2 (paricalcitol)

Effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines

István Molnár, Timothy Kute, Mark C. Willingham, Bayard L. Powell, William H. Dodge, Gary Schwartz

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: 19-Nor-1α,25-dihydroxyvitamin D2 (paricalcitol) is an analogue of 1,25(OH)2D3 with reduced calcemic effects that is approved for the suppression of parathyroid hormone in chronic renal failure. Paricalcitol has recently been reported to have anticancer activity in prostate cancer. In order to explore paricalcitol as a potential agent against leukemia, we tested its effects on HL-60 and U937 leukemia cell lines. Methods: We studied cellular differentiation via expression of CD11b and CD14 surface antigens using flow cytometry, and via the nitroblue tetrazolium (NBT) assay. Cell cycle was analyzed using propidium iodide staining. Apoptosis was assessed with the annexin V assay. Cellular proliferation was determined via colony inhibition on semisolid medium. Results: Paricalcitol induced the maturation of HL-60 and U937 cells, as shown by increased expression of CD11b differentiation surface antigen. CD14 showed increased expression in HL-60 but not in U937 cells. After exposure to paricalcitol at 10-8 M for 72 h, the ability of HL-60 cells to reduce NBT was markedly increased. Conversely, U937 cells were unchanged. Paricalcitol inhibited colony formation of both HL-60 and U937 cell lines in semisolid medium after a 10-day incubation (estimated IC50 of 3×10-8 M in HL-60 cells and 4×10-8 M in U937 cells). Paricalcitol at 10-8 M and 10-7 M caused a significant dose- and time-dependent increase of apoptosis in HL-60 cells (P<0.05). In both HL-60 and U937 cells, exposure to 10-7 M paricalcitol for 72 h increased the number of cells in G0/G1 phase, and decreased the number of cells in S phase. Conclusions: Paricalcitol inhibits colony formation, induces maturation and causes cell cycle arrest in HL-60 and U937 cells. Additionally, paricalcitol induces apoptosis in HL-60 cells. These findings support the further evaluation of paricalcitol as an antileukemia agent.

Original languageEnglish (US)
Pages (from-to)35-42
Number of pages8
JournalJournal of Cancer Research and Clinical Oncology
Volume129
Issue number1
StatePublished - Jan 1 2003

Fingerprint

U937 Cells
HL-60 Cells
Apoptosis
Cell Line
Nitroblue Tetrazolium
Surface Antigens
CD11b Antigens
Leukemia
paricalcitol
1,25-dihydroxyergocalciferol
Cell Count
CD14 Antigens
Cell Cycle Resting Phase
Propidium
Annexin A5
Differentiation Antigens
G1 Phase
Cell Cycle Checkpoints
Parathyroid Hormone
S Phase

Keywords

  • Apoptosis
  • Differentiation
  • Experimental therapeutics
  • HL-60
  • Paricalcitol
  • U937

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

19-Nor-1α, 25-dihydroxyvitamin D2 (paricalcitol) : Effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines. / Molnár, István; Kute, Timothy; Willingham, Mark C.; Powell, Bayard L.; Dodge, William H.; Schwartz, Gary.

In: Journal of Cancer Research and Clinical Oncology, Vol. 129, No. 1, 01.01.2003, p. 35-42.

Research output: Contribution to journalArticle

Molnár, István ; Kute, Timothy ; Willingham, Mark C. ; Powell, Bayard L. ; Dodge, William H. ; Schwartz, Gary. / 19-Nor-1α, 25-dihydroxyvitamin D2 (paricalcitol) : Effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines. In: Journal of Cancer Research and Clinical Oncology. 2003 ; Vol. 129, No. 1. pp. 35-42.
@article{26606336a55a46cd8a6b89d9dca78456,
title = "19-Nor-1α, 25-dihydroxyvitamin D2 (paricalcitol): Effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines",
abstract = "Purpose: 19-Nor-1α,25-dihydroxyvitamin D2 (paricalcitol) is an analogue of 1,25(OH)2D3 with reduced calcemic effects that is approved for the suppression of parathyroid hormone in chronic renal failure. Paricalcitol has recently been reported to have anticancer activity in prostate cancer. In order to explore paricalcitol as a potential agent against leukemia, we tested its effects on HL-60 and U937 leukemia cell lines. Methods: We studied cellular differentiation via expression of CD11b and CD14 surface antigens using flow cytometry, and via the nitroblue tetrazolium (NBT) assay. Cell cycle was analyzed using propidium iodide staining. Apoptosis was assessed with the annexin V assay. Cellular proliferation was determined via colony inhibition on semisolid medium. Results: Paricalcitol induced the maturation of HL-60 and U937 cells, as shown by increased expression of CD11b differentiation surface antigen. CD14 showed increased expression in HL-60 but not in U937 cells. After exposure to paricalcitol at 10-8 M for 72 h, the ability of HL-60 cells to reduce NBT was markedly increased. Conversely, U937 cells were unchanged. Paricalcitol inhibited colony formation of both HL-60 and U937 cell lines in semisolid medium after a 10-day incubation (estimated IC50 of 3×10-8 M in HL-60 cells and 4×10-8 M in U937 cells). Paricalcitol at 10-8 M and 10-7 M caused a significant dose- and time-dependent increase of apoptosis in HL-60 cells (P<0.05). In both HL-60 and U937 cells, exposure to 10-7 M paricalcitol for 72 h increased the number of cells in G0/G1 phase, and decreased the number of cells in S phase. Conclusions: Paricalcitol inhibits colony formation, induces maturation and causes cell cycle arrest in HL-60 and U937 cells. Additionally, paricalcitol induces apoptosis in HL-60 cells. These findings support the further evaluation of paricalcitol as an antileukemia agent.",
keywords = "Apoptosis, Differentiation, Experimental therapeutics, HL-60, Paricalcitol, U937",
author = "Istv{\'a}n Moln{\'a}r and Timothy Kute and Willingham, {Mark C.} and Powell, {Bayard L.} and Dodge, {William H.} and Gary Schwartz",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
volume = "129",
pages = "35--42",
journal = "Zeitschrift fur Krebsforschung und Klinische Onkologie",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - 19-Nor-1α, 25-dihydroxyvitamin D2 (paricalcitol)

T2 - Effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines

AU - Molnár, István

AU - Kute, Timothy

AU - Willingham, Mark C.

AU - Powell, Bayard L.

AU - Dodge, William H.

AU - Schwartz, Gary

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Purpose: 19-Nor-1α,25-dihydroxyvitamin D2 (paricalcitol) is an analogue of 1,25(OH)2D3 with reduced calcemic effects that is approved for the suppression of parathyroid hormone in chronic renal failure. Paricalcitol has recently been reported to have anticancer activity in prostate cancer. In order to explore paricalcitol as a potential agent against leukemia, we tested its effects on HL-60 and U937 leukemia cell lines. Methods: We studied cellular differentiation via expression of CD11b and CD14 surface antigens using flow cytometry, and via the nitroblue tetrazolium (NBT) assay. Cell cycle was analyzed using propidium iodide staining. Apoptosis was assessed with the annexin V assay. Cellular proliferation was determined via colony inhibition on semisolid medium. Results: Paricalcitol induced the maturation of HL-60 and U937 cells, as shown by increased expression of CD11b differentiation surface antigen. CD14 showed increased expression in HL-60 but not in U937 cells. After exposure to paricalcitol at 10-8 M for 72 h, the ability of HL-60 cells to reduce NBT was markedly increased. Conversely, U937 cells were unchanged. Paricalcitol inhibited colony formation of both HL-60 and U937 cell lines in semisolid medium after a 10-day incubation (estimated IC50 of 3×10-8 M in HL-60 cells and 4×10-8 M in U937 cells). Paricalcitol at 10-8 M and 10-7 M caused a significant dose- and time-dependent increase of apoptosis in HL-60 cells (P<0.05). In both HL-60 and U937 cells, exposure to 10-7 M paricalcitol for 72 h increased the number of cells in G0/G1 phase, and decreased the number of cells in S phase. Conclusions: Paricalcitol inhibits colony formation, induces maturation and causes cell cycle arrest in HL-60 and U937 cells. Additionally, paricalcitol induces apoptosis in HL-60 cells. These findings support the further evaluation of paricalcitol as an antileukemia agent.

AB - Purpose: 19-Nor-1α,25-dihydroxyvitamin D2 (paricalcitol) is an analogue of 1,25(OH)2D3 with reduced calcemic effects that is approved for the suppression of parathyroid hormone in chronic renal failure. Paricalcitol has recently been reported to have anticancer activity in prostate cancer. In order to explore paricalcitol as a potential agent against leukemia, we tested its effects on HL-60 and U937 leukemia cell lines. Methods: We studied cellular differentiation via expression of CD11b and CD14 surface antigens using flow cytometry, and via the nitroblue tetrazolium (NBT) assay. Cell cycle was analyzed using propidium iodide staining. Apoptosis was assessed with the annexin V assay. Cellular proliferation was determined via colony inhibition on semisolid medium. Results: Paricalcitol induced the maturation of HL-60 and U937 cells, as shown by increased expression of CD11b differentiation surface antigen. CD14 showed increased expression in HL-60 but not in U937 cells. After exposure to paricalcitol at 10-8 M for 72 h, the ability of HL-60 cells to reduce NBT was markedly increased. Conversely, U937 cells were unchanged. Paricalcitol inhibited colony formation of both HL-60 and U937 cell lines in semisolid medium after a 10-day incubation (estimated IC50 of 3×10-8 M in HL-60 cells and 4×10-8 M in U937 cells). Paricalcitol at 10-8 M and 10-7 M caused a significant dose- and time-dependent increase of apoptosis in HL-60 cells (P<0.05). In both HL-60 and U937 cells, exposure to 10-7 M paricalcitol for 72 h increased the number of cells in G0/G1 phase, and decreased the number of cells in S phase. Conclusions: Paricalcitol inhibits colony formation, induces maturation and causes cell cycle arrest in HL-60 and U937 cells. Additionally, paricalcitol induces apoptosis in HL-60 cells. These findings support the further evaluation of paricalcitol as an antileukemia agent.

KW - Apoptosis

KW - Differentiation

KW - Experimental therapeutics

KW - HL-60

KW - Paricalcitol

KW - U937

UR - http://www.scopus.com/inward/record.url?scp=0038777279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038777279&partnerID=8YFLogxK

M3 - Article

VL - 129

SP - 35

EP - 42

JO - Zeitschrift fur Krebsforschung und Klinische Onkologie

JF - Zeitschrift fur Krebsforschung und Klinische Onkologie

SN - 0171-5216

IS - 1

ER -